www.treatu.pt! João Nuno Moreira! Center for Neurosciences and Cell Biology! Faculty of Pharmacy! University of Coimbra www.treatu.pt! TREAT U is a spin-off from the University of Coimbra/CNC, Portugal.! TREAT U was founded in 2010 and started activity in 2012.! University of Coimbra Biocant Park Funding from Ministry of Economy FDA approved Pharmaceu1cal Company Venture Capital JN Moreira 2015 jmoreira@ff.uc.pt DRUG DELIVERY PLATAFORM! We have developed a safe, fast and efficient drug delivery platform to target the tumor microenvironment:! PEGASEMP™ ! towards ! UNMET MEDICAL NEEDS: ! Breast cancer! Lung cancer! Triple negative! Pleomorphic! Metastatic breast cancer! Adenocarcinoma! DRUG JN Moreira 2015 jmoreira@ff.uc.pt PEGASEMP™: novel mechanism of drug delivery! (hCps://www.dropbox.com/s/m94xvfaf6macjrz/PEGASEMP.m4v?dl=0) JN Moreira 2015 jmoreira@ff.uc.pt PEGASEMP™: proof of concept! (Orthotopic animal model)! PEGASEMPTM! • Faster tumor accumulation (just within 4 h after IV)! Suppression of tumor invasiveness! • Tumor uptake 4–fold higher than the control! • 50% reduction of the viable peripheral area;! • More evident signs of extensive cell death at the periphery of the tumor;! • 75% decrease in microvascular density within the tumor.! Non-Targeted! JN Moreira 2015 jmoreira@ff.uc.pt Intellectual Property! USA EUROPE US Patent granted in 2012! (Ref 8,231,895)! Applicant: University of Coimbra, CNC! US Patent Divisional granted in 2013! (Ref 8,529,944)! Applicant: University of Coimbra, CNC! US Patent Divisional granted in 2014! (Ref 8,741,338)! Applicant: University of Coimbra, CNC! PCT filed! Patent under examination! JN Moreira 2015 jmoreira@ff.uc.pt • Compe11ve advantage; • Technology roadmap and development… • …for more informa1on, contact João Nuno Moreira ( jmoreira@ff.uc.pt) JN Moreira 2015 jmoreira@ff.uc.pt Acknowledgments h"p://moreirajn.wix.com/jnmoreiragroup • Vera Moura, PhD • Nuno Fonseca • Ana Gregório • Ângela Fernandes • Ana Cruz • Sofia Romano • Mariangela Natale • Rui Lopes, PhD • Marta Pereira, MD • Susana Cecílio • Rute Araújo • Adriana Santos • Lígia Silva • Luís Bimbo • Carla Gomes • Luís Rocha • Sarah Pagliaro • Vanessa Monteiro CNC/UC Sérgio Simões Luís Almeida Group of Vectors and Gene Therapy Portuguese Ins2tute of Oncology (Coimbra) Paulo Figueiredo, MD Manuela Lacerda, MD Ins2tute of Anatomical and Molecular Pathology, Faculty of Medicine and University Hospital of Coimbra Lina Carvalho, MD The Team Sérgio Simões PharmD, MSc, PhD João Nuno Moreira PharmD, MSc, PhD Chairman, Co-Founder Scientific Advisor, Co-Founder Vice President of Bluepharma Co-founder of 3 spin-offs Professor at the Faculty of Pharmacy Principal Investigator at CNC, University of Coimbra Vera Dantas Moura Luís Almeida PharmD, PhD M.D., PhD CEO, Co-Founder Scientific Advisor Investigator at University of Coimbra CEO of Luzitin, SA Former Head of Clinical Research at Bial Co-founder and CEO of Blueclinical, Lda Amílcar Falcão Tony Cruz PharmD, PhD M.D., PhD Scientific Advisor Business Advisor Vice-rector at University of Coimbra CEO of Transition Therapeutics Co-Founder, Vice-President and Director at Angiotech Pharmaceuticals Inc. Consultant for biotechnology companies and investment firms Portugal Capital Ventures – Sociedade de Capital de Risco, S.A. Bluepharma – Indústria Farmacêutica, S.A.
Download
